Joe Cintavey

1 month ago | bioprocessonline.com | David Seifert |Joe Cintavey |W.L. Gore |Tyler Menichiello

BoB@JPM: Tom Chalberg, Ph.D., GenascenceJoin Business of Biotech’s Matt Pillar and Ben Comer as they dive into the future of gene therapy with Dr. Tom Chalberg, CEO of Genascence. The discussion explores the shift from rare disease treatments to common conditions like osteoarthritis, the challenges of delivery and regulation, and Genascence’s partnership strategy.